中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2012年
5期
535-538
,共4页
锥形束CT%吸收剂量%当量剂量%有效剂量
錐形束CT%吸收劑量%噹量劑量%有效劑量
추형속CT%흡수제량%당량제량%유효제량
Cone beam computed tomography%Absorbed dosage%Equivalent dosage%Effective dosage
目的 测算Implagraphy牙颌面锥形束CT(CBCT)体模不同扫描体位的组织器官吸收剂量、当量剂量及有效剂量,为相应的防护措施提供客观依据.方法 使用仿真成年男性头颈部体模及热释光剂量计,分别测量Implagraphy CBCT下颌、上颌及颞下颌关节(TMJ)扫描时脑垂体、眼晶状体、腮腺、颌下腺、舌下腺、颅骨板障、下颌松质骨、颈椎松质骨、颊部皮肤、颈部皮肤、甲状腺、食管及口腔黏膜等组织器官的吸收剂量,计算眼晶状体、皮肤的当量剂量,及Implagraphy CBCT不同扫描体位的有效剂量E1990及E2007.结果 Implagraphy CBCT各扫描体位的吸收剂量分别为:下颌扫描(0.99 ±0.09) ～(12.85±0.09) mGy,上颌扫描(0.93 ±0.01)～(13.07 ±0.02) mGy,TMJ扫描(0.68±0.01)～(10.18 ±0.04) mGy,相同组织器官在不同扫描体位的吸收剂量的差异具有统计学意义(F=19.61～ 30992.27,P＜0.05).在不同扫描体位,眼晶状体及皮肤的当量剂量分别为(1.11±0.07) ～ (5.76±0.06) mSv和(6.96±0.06) ～ (10.64±0.07) mSv,差异具有统计学意义(F=4473.02、9385.50,P＜0.05).有效剂量E1990及E2007分别为:下颌扫描(191.35±1.53)和(325.17±2.58)μSv,上颌扫描(106.62±2 17)和(226.28±2.81)μSv,TMJ扫描(104.21±1.02)和(142.36±1.90) μSv.结论 在牙颌面CBCT检查过程中,采用尽可能小的扫描视野、准确地扫描体位,正确使用铅胶帽、围领及防护镜等屏蔽措施,使X射线辐射照射保持在可以合理达到的尽可能低的水平.
目的 測算Implagraphy牙頜麵錐形束CT(CBCT)體模不同掃描體位的組織器官吸收劑量、噹量劑量及有效劑量,為相應的防護措施提供客觀依據.方法 使用倣真成年男性頭頸部體模及熱釋光劑量計,分彆測量Implagraphy CBCT下頜、上頜及顳下頜關節(TMJ)掃描時腦垂體、眼晶狀體、腮腺、頜下腺、舌下腺、顱骨闆障、下頜鬆質骨、頸椎鬆質骨、頰部皮膚、頸部皮膚、甲狀腺、食管及口腔黏膜等組織器官的吸收劑量,計算眼晶狀體、皮膚的噹量劑量,及Implagraphy CBCT不同掃描體位的有效劑量E1990及E2007.結果 Implagraphy CBCT各掃描體位的吸收劑量分彆為:下頜掃描(0.99 ±0.09) ～(12.85±0.09) mGy,上頜掃描(0.93 ±0.01)～(13.07 ±0.02) mGy,TMJ掃描(0.68±0.01)～(10.18 ±0.04) mGy,相同組織器官在不同掃描體位的吸收劑量的差異具有統計學意義(F=19.61～ 30992.27,P＜0.05).在不同掃描體位,眼晶狀體及皮膚的噹量劑量分彆為(1.11±0.07) ～ (5.76±0.06) mSv和(6.96±0.06) ～ (10.64±0.07) mSv,差異具有統計學意義(F=4473.02、9385.50,P＜0.05).有效劑量E1990及E2007分彆為:下頜掃描(191.35±1.53)和(325.17±2.58)μSv,上頜掃描(106.62±2 17)和(226.28±2.81)μSv,TMJ掃描(104.21±1.02)和(142.36±1.90) μSv.結論 在牙頜麵CBCT檢查過程中,採用儘可能小的掃描視野、準確地掃描體位,正確使用鉛膠帽、圍領及防護鏡等屏蔽措施,使X射線輻射照射保持在可以閤理達到的儘可能低的水平.
목적 측산Implagraphy아합면추형속CT(CBCT)체모불동소묘체위적조직기관흡수제량、당량제량급유효제량,위상응적방호조시제공객관의거.방법 사용방진성년남성두경부체모급열석광제량계,분별측량Implagraphy CBCT하합、상합급섭하합관절(TMJ)소묘시뇌수체、안정상체、시선、합하선、설하선、로골판장、하합송질골、경추송질골、협부피부、경부피부、갑상선、식관급구강점막등조직기관적흡수제량,계산안정상체、피부적당량제량,급Implagraphy CBCT불동소묘체위적유효제량E1990급E2007.결과 Implagraphy CBCT각소묘체위적흡수제량분별위:하합소묘(0.99 ±0.09) ～(12.85±0.09) mGy,상합소묘(0.93 ±0.01)～(13.07 ±0.02) mGy,TMJ소묘(0.68±0.01)～(10.18 ±0.04) mGy,상동조직기관재불동소묘체위적흡수제량적차이구유통계학의의(F=19.61～ 30992.27,P＜0.05).재불동소묘체위,안정상체급피부적당량제량분별위(1.11±0.07) ～ (5.76±0.06) mSv화(6.96±0.06) ～ (10.64±0.07) mSv,차이구유통계학의의(F=4473.02、9385.50,P＜0.05).유효제량E1990급E2007분별위:하합소묘(191.35±1.53)화(325.17±2.58)μSv,상합소묘(106.62±2 17)화(226.28±2.81)μSv,TMJ소묘(104.21±1.02)화(142.36±1.90) μSv.결론 재아합면CBCT검사과정중,채용진가능소적소묘시야、준학지소묘체위,정학사용연효모、위령급방호경등병폐조시,사X사선복사조사보지재가이합리체도적진가능저적수평.
Objective To evaluate the subject's absorbed dose,equivalent dose and effective dose.Methods The CBCT unit was Implagraphy and three scan projections were selected such as mandible,maxilla and temporamandibular joint (TMJ).Thermoluminescent dosimeter tubes were used to record the absorbed dose at special positions in the head and neck region of an adult skull and tissue-equivalent phantom.16 interested organs included pituitary,lens,parotid glands,submandibular glands,sublingual glands、diploe,spongy bone of the chin and cervical vertebra,skins of cheeks and nuchal region,thyroid and esophagus.The absorbed dose was measured in these organs,and then the effective dose(E1990,E2007)were calculated according to different ICRP tissue weighting factors.Results The absorbed dose of mandible,maxilla and TMJ scan varied from (0.99 ±0.09) to (12.85 ±0.09)mGy,(0.93 ±0.01) to (13.07 ±0.02) mGy and (0.68 ±0.01) to (10.18 ± 0.04)mGy.There was significant difference among the three scan projections (F =19.61-30992.27,p ＜ 0.05).The equivalent doses of lens and skin were (1.11± 0.07)-(5.76 ± 0.06) mSv and (6.96 ± 0.06)-(10.64 ± 0.07) mSv.There was significant difference among the three scan projections(F =4473.02,9385.50,P ＜0.05).The effective dose(E1990,E2oo7) was [(191.35±1.53),(325.17 ±2.58) μSv] for mandible scan,[(106.62 ±2.17),(226.28 ±2.81)μSv] for maxilla scan,[(104.21 ± 1.02),(142.36 ± 1.90) μSv]for TMJ scan,respectively.Conclusions The valid measurement should be taken to reduce the subject' s dose such as a careful history and clinical examination before the performance of CBCT,the latest risk/benefit assessment,precise scan position,the shielding of thyroid as well as brain and the smaller volume size as well.
